4//SEC Filing
Krassan Mitchell 4
Accession 0001387131-20-003591
CIK 0000025743other
Filed
Mar 31, 8:00 PM ET
Accepted
Apr 1, 8:32 PM ET
Size
8.7 KB
Accession
0001387131-20-003591
Insider Transaction Report
Form 4
Krassan Mitchell
EVP, Chief Strategy Officer
Transactions
- Award
Performance Stock Units
2020-03-30+151,500→ 151,500 totalExercise: $0.00→ Common Stock (151,500 underlying) - Award
Restricted Stock Units
2020-03-30+151,500→ 151,500 totalExercise: $0.00→ Common Stock (151,500 underlying)
Footnotes (2)
- [F1]The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer.
- [F2]Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 30, 2021, becoming fully vested on March 30, 2023.
Documents
Issuer
TherapeuticsMD, Inc.
CIK 0000025743
Entity typeother
Related Parties
1- filerCIK 0001532232
Filing Metadata
- Form type
- 4
- Filed
- Mar 31, 8:00 PM ET
- Accepted
- Apr 1, 8:32 PM ET
- Size
- 8.7 KB